Albertsons Companies Showcases Certified Products for Earth Month
See original post on Instagram and read more about Albertsons Companies and our Recipe for Change on our website.
Visit 3BL Media to see more multimedia and stories from Albertsons Safeway Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14 minutes ago
- Business Wire
Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the 'Investor Relations' section of the Establishment Labs website at About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO 13485:2016 and FDA 21 CFR 820. Please visit our website for additional information at
Business Upturn
an hour ago
- Business Upturn
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
EMA's CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) Roche will continue its dialogue with the EMA to explore a potential path forward to make Elevidys available to individuals living with DMD in the EU Roche believes the benefit-risk remains positive in the ambulatory Duchenne population Elevidys is the first and only disease-modifying gene therapy for DMD Basel, 25 July 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys™ (delandistrogene moxeparvovec) for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD). Given the high unmet need in DMD, Roche plans to continue to work with the EMA to explore a potential path forward. 'We are disappointed by the CHMP's negative opinion, given the urgent need for disease-modifying therapies for children in the EU living with Duchenne,' said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development, Roche. 'With an average life expectancy of only 28 years, achieving disease stabilisation is a major advance for individuals living with Duchenne, their families and caregivers. We are confident in the value Elevidys can bring to ambulatory patients.' The CHMP opinion is based on data from the largest and broadest gene therapy clinical programme in DMD to date, including results from the pivotal Phase III EMBARK study that showed treatment with Elevidys provided sustained stabilisation or slowing of disease progression, and a consistent and manageable safety profile in ambulatory patients. To date, more than 900 individuals with DMD, 760 of whom are ambulatory, have been treated with Elevidys in clinical and real-world settings. While the primary endpoint was not met in EMBARK after one year, Elevidys showed clinically meaningful and statistically significant improvements across important secondary endpoints of functional outcome measures when compared to placebo. Longer term efficacy data were also submitted to EMA, including two-year results from the EMBARK study and three-year pooled efficacy analysis from three other Elevidys studies that showed clinically meaningful improvements across key measures of motor function. One-year data from part one of the EMBARK study were published in Nature Medicine in October 2024 and results from year two were shared at this year's Muscular Dystrophy Association clinical & scientific conference in Dallas, TX. DMD is a rare, genetic, muscle-wasting disease that progresses rapidly from early childhood. Everyone with Duchenne will eventually lose the ability to walk, along with upper limb, lung, and cardiac function. Average life expectancy is only 28 years. The physical, emotional, and financial impact of Duchenne on those affected, their families, and caregivers, is profound. Roche recognises there is a significant unmet medical need for those living with Duchenne and the urgency for treating children before DMD progresses to provide the best possible chance for improved outcomes. We are actively working with health authorities across the globe to bring Elevidys to patients and their families as soon as possible. Elevidys is the first and only approved gene therapy targeting the underlying cause of disease that consistently demonstrates stabilisation or slowing of DMD disease progression, with durable effects on functional and biological outcomes and muscle health. About Duchenne muscular dystrophy DMD primarily affects males, with 1 in 5,000 boys born worldwide having Duchenne. Everyone with Duchenne will eventually lose the ability to walk, along with upper limb, lung and cardiac function. Average life expectancy is only 28 years. The physical, emotional and financial impact of Duchenne on those affected, their families and caregivers, is profound. Duchenne is an X-linked, rare neuromuscular disease caused by pathogenic variants (mutations) in the DMD gene that disrupt the production of functional dystrophin protein, leading to progressive and irreversible muscle weakness, diminished quality of life and premature death. Dystrophin strengthens and protects muscles and without it, normal activity causes excessive damage to muscle cells as they are more sensitive to injury. Over time, muscle tissue is replaced with scar tissue and fat, causing muscles to weaken. Although Duchenne progresses differently in each individual, its devastating trajectory is well established. Those with Duchenne will eventually lose the ability to use and move their limbs, to breathe on their own and are susceptible to respiratory infections. Muscle damage to the heart causes cardiomyopathy, including rhythm abnormalities and heart failure. Early diagnosis is important for timely intervention to prolong muscle function and preserve quality of life. There is a critical need for disease-modifying treatments that address the underlying cause of DMD before irreversible muscle loss occurs. About Elevidys™ (delandistrogene moxeparvovec) Elevidys™ (delandistrogene moxeparvovec, also known as SRP-9001) is the first approved disease-modifying gene therapy for Duchenne and is designed to address the underlying cause of Duchenne through targeted skeletal, respiratory and cardiac muscle expression of shortened dystrophin produced by Elevidys. Elevidys is a one-time treatment administered through a single intravenous dose. Elevidys is contraindicated in individuals with any deletion in exons 8 and/or 9 in the DMD gene. Elevidys has been studied in the largest and broadest gene therapy clinical development program in DMD with the longest follow-up (up to six years) in patients of all ages, and with various DMD mutations. To date, more than 900 individuals with DMD (more than 760 of whom are ambulatory) have been treated with Elevidys across clinical and real-world settings and Elevidys is now approved in nine countries, including Japan. Important Elevidys Updates: On 15 June, Roche announced new dosing restrictions for Elevidys for non-ambulatory DMD patients, irrespective of age, in both clinical and commercial settings. These measures followed two reported fatalities in the non-ambulatory DMD population. On 22 July, in response to the U.S. Food and Drug Administration (FDA)'s request to Sarepta, Roche took additional measures towards initiating a voluntary and temporary pause of any new orders of Elevidys to countries outside the U.S. that reference the FDA as the basis for their local approval, and in Named Patient Supply (NPS) countries. Discussions with other relevant health authorities are ongoing. Roche will immediately respect requests to halt new orders and shipments from health authorities. Patient safety is Roche's highest priority. Based on the totality of available data, Roche believes that the benefit-risk profile is positive in the ambulatory patient population. To date, approximately 760 ambulatory DMD patients have been treated with Elevidys in clinical and real-world settings and there have been no treatment-related fatalities. Elevidys is being developed by Roche in collaboration with Sarepta Therapeutics About Roche in Neuroscience Neuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: [email protected] Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Investor Relations North America Loren KalmPhone: +1 650 225 3217 e-mail: [email protected] Attachment Media Investor Release Elevidys CHMP Opinion English Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
an hour ago
- Yahoo
VSAT Market worth $19.29 billion by 2030 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., July 25, 2025 /PRNewswire/ -- The VSAT (Very Small Aperture Terminal) market is estimated at USD 14.14 billion in 2025 and is projected to reach USD 19.29 billion by 2030 at a CAGR of 6.4% during the forecast period according to a new report by MarketsandMarkets™. The VSAT market is witnessing strong growth globally, fueled by rising demand for high-speed internet in remote and underserved regions across sectors like maritime, defense, and energy. Government-backed rural broadband programs and disaster recovery initiatives are accelerating deployments. Technological advancements such as high-throughput satellites (HTS) and low-Earth orbit (LEO) constellations are improving connectivity performance and reducing latency. Increased adoption of mobility solutions in aviation, land transport, and maritime further boosts the market. Additionally, growing enterprise reliance on real-time data, IoT, and cloud services is driving VSAT penetration globally. Download PDF Brochure: Browse in-depth TOC on "VSAT Market" 140 – Tables80 – Figures280 – Pages VSAT Market Report Scope: Report Coverage Details Market Revenue in 2025 $ 14.14 billion Estimated Value by 2030 $ 19.29 billion Growth Rate Poised to grow at a CAGR of 6.4% Market Size Available for 2020–2030 Forecast Period 2025–2030 Forecast Units Value (USD Million/Billion) Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends Segments Covered By End Use, Application, Frequency, Network and Region Geographies Covered North America, Europe, Asia Pacific, and Rest of World Key Market Challenge Radio spectrum availability issues Key Market Opportunities Growing demand for autonomous and connected vehicles Key Market Drivers Increasing use of VSAT technology in maritime industry Based on applications, the maritime segment is estimated to account for the largest market share in 2025. Based on application, the maritime segment is estimated to account for the largest market share in the VSAT market in 2025. The maritime segment is witnessing growth due to the growing demand for fast and secure satellite connectivity in the high seas. Cruise ships, commercial shipping firms, offshore oil and gas platforms, naval defense ships, and fishing vessels are primary users of maritime VSAT services. These vessels often operate out of shore-based communication facilities, and therefore, satellite connectivity is essential for navigation, crew comfort, monitoring of cargo, remote diagnostics, and control operations. The necessary IMO requirements for reporting and compliance in terms of cybersecurity are also driving the adoption of VSAT at a quicker pace. Furthermore, the growth in digital ship operations, weather-based real-time routing, and IoT-based monitoring systems is increasing the bandwidth requirements of maritime platforms. Widespread use of compact terminals and stabilized antennas suitable for ships of any size, coupled with the low cost of service packages offered by VSAT providers, is fueling adoption by developed and emerging economies. Based on network, the standard VSAT segment is projected to register the highest CAGR during the forecast period. Based on network, the standard VSAT segment is projected to register the highest CAGR during the forecast period. This is due to its extensive use in enterprises, commercial, and government markets. Standard VSAT systems operate in fixed or semi-fixed configurations and are extensively used in broadband internet access, corporate network extension, remote learning, telemedicine, and disaster recovery. The expansion of public service and business digitalization, particularly in rural regions, has enabled higher dependence upon standard VSAT installations to provide connectivity where terrestrial supply is not available. The terminals are also used extensively in government initiatives for rural broadband deployment as well as emergency communications infrastructure. With the emergence of high-throughput satellites (HTS), standard VSAT systems became more economical and efficient, leading to increased penetration in emerging and developed economies. The ease of their deployments, scalability, and compatibility with Ku- and Ka-band satellites ensure that they are an economic solution, fueling their growth in the global VSAT market. Inquiry Before Buying: Asia Pacific is projected to register the highest CAGR during the forecast period. The VSAT industry in Asia Pacific is projected to record the highest CAGR during the forecast period due to its vast geography, large, underserved population, and rapid digitalization efforts across several emerging economies. Countries like India, Indonesia, the Philippines, and Vietnam face high challenges in the deployment of ground broadband networks due to topography issues, huge investment requirements, and a dispersed rural population. The emergence of indigenous satellite programs and the accessibility of indigenous satellite service providers are making VSAT services affordable and localized. Operationsnes, shipping companies, defense bodies, and mining operations are also employing mobile VSAT terminals for reliable connectivity while in transit or offshore. Asia Pacific is also a significant production and R&D hub for VSAT equipment, which reduces costs and enhances affordability. With strong economic growth, public-private partnership business models, and increasing digital penetration targets, Asia Pacific presents high-growth opportunities in the VSAT market. Key Players in the VSAT companies are Orbit Communication Systems Ltd. (Israel), L3Harris Technologies Inc (US), Viasat Inc. (US), Gilat Satellite Networks Ltd. (Israel), ST Engineering iDirect, Inc (US), General Dynamics Corporation (US), Ultra Electronics (UK), Honeywell International Inc. (US), Thales Group (France), KVH Industries, Inc. (US), Singtel (Singapore), Mitsubishi Electric Corporation (Japan), EchoStar Corporation (US), Comtech Telecommunications Corporation (US), and SatixFy Communications Ltd. (Israel). Get 10% Free Customization on this Report: Browse Adjacent Market: Aerospace and Defence Market Research Reports &Consulting See More Latest Aerospace and Defence Reports: Military (Mil-Spec) Connectors Market by Shape {Circular [Mil-DTL-(38999,26482,5015)], Rectangular [MIL-DTL-(24308, 83513, 55302)]}, Type (Power, Signal, Data, RF & Microwave, Fiber Optic, Hybrid), Platform, Point of Sale and Region - Global Forecast to 2030 Artificial Intelligence (AI) in Drones Market by Solution (Infrastructure, Software, Services), Function (Flight Operations, Maintenance, Ground Control, Asset Health, Simulation, Revenue Optimization), End User, Technology - Global Forecast to 2030 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Web Site: Insight: Source: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
